• Home
  • Search Results

Research Studies

UNC-Chapel Hill Lineberger Comprehensive Cancer Center

Cancer - Lymphoma
36 studies match your search
Open

Phase Ib/II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) and CCR4 for Relapsed/Refractory CD30+ Hodgkin s Lymphoma

Do you have a type of cancer known as Relapsed Hodgkin's Lymphoma?Has your cancer come back, or not get better with the last treatment you received ? If so, you may be able to participate in a gene therapy study to see if we can use your body's own immune cells as a treatment for your HL. (Example: Do you know your blood pressure? Do you sit too much at work? If you have a desk job and higher than normal blood pressure (but are not taking blood pressure medication), you may be able to participate in a research study to find out if sitting less during the workday can lower

Age & Gender
  • 3 years ~ 17 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Lymphoma)
Not currently enrolling

Optimizing Nutrition and Exercise in Childhood Acute Lymphoblastic Leukemia

In this study, we want to determine if dietary intervention is feasible for patients being treated for leukemia or lymphoma.

Age & Gender
  • 8 years ~ 21 years
  • Male, Female
Study Interest
  • Cancer (Leukemia, Lymphoma)
Open

Cancer Family History in Black Families

The survey and its findings will help us understand attitudes around cancer family history and genetic testing among Black people. This information will be used to develop an educational curriculum to strive towards health equity for Black people diagnosed with or at higher risk of cancer and get Black people the best cancer care.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Bladder, Brain and Other Nervous System, Breast, and 18 more)
  • Healthy Volunteer or General Population
  • Minority Health
Visit Location
100% Remote (online, phone, text)

A Comparator Study of a Tasso device to traditional venous blood sampling methods for CBC in patients with leukemia, lymphoma, or other blood cell disorders

This study will evaluate the feasibility of using capillary blood samples collected with the Tasso device for analysis of CBC in diseased patients with leukemia, lymphoma, and/or other blood cell disorders.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Conditions
  • Cancer (Leukemia, Lymphoma)
Open

Cancer Research Study for Bertie, Hertford, Robeson & Scotland Co, NC and neighboring counties

We are seeking volunteers for a survey to learn what may encourage and discourage cancer patients to be in cancer research studies. We'd like to hear from you if you are: -18 years+ -Have been diagnosed with cancer or the caregiver of someone diagnosed with cancer. -Spend time in Bertie, Hertford, Robeson or Scotland County, NC or a neighboring county. Participation includes 1 survey (about 10 minutes long) that can be done with your mobile device, computer, or by phone with the researcher. Compensation: 1 in 10 participants will receive a $25 Visa gift card.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Bladder, Brain and Other Nervous System, Breast, and 20 more)
Visit Location
100% Remote (online, phone, text)

Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With Recurrent or Refractory Hodgkin Lymphoma and CD-30 Positive Peripheral T-Cell Lymphoma (LuminICE-203)

This study enrolling people who recurrent (has come back) or refractory (did not respond to treatment) classical Hodgkin lymphoma or CD30-positive peripheral T-cell lymphoma (PTCL). The purpose of this study is to learn about the effectiveness and safety of a new study drug called AFM13 when used in combination with a new cell therapy called AB-101. The study will also look at how the body processes this combination of drugs (called "pharmacokinetics").

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Lymphoma)
Open

Young Adult Cancer Survivors Healthy Eating and Active Lifestyle Study

Are you a young adult cancer survivor who would like to improve your health? Interested in using technology to support a healthy diet, get more physically active, and make healthy lifestyle changes? Researchers at the University of North Carolina at Chapel Hill are looking for volunteers to sign up for a 3-month research program using a Fitbit activity tracker and mobile app to improve your physical activity and dietary habits.

Age & Gender
  • 18 years ~ 39 years
  • Male, Female, Gender Inclusive
Study Interest
  • Behavior
  • Eating, Nutrition, and Metabolism
  • Wellness and Lifestyle
  • and 3 more
Visit Location
100% Remote (online, phone, text)
Open

Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder

Have you been diagnosed with B-cell post-transplant lymphoproliferative disorder (PTLD) after an organ transplant? Have you not yet received any type of treatment for this condition? Then you may be eligible for a study to look at the safety and effectiveness of tafasitamab and rituximab combination treatment for PTLD.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Conditions
  • Cancer (Lymphoma)
  • Transplant

Characterization of Circulating Tumor DNA Kinetics During Radiation Therapy, Treatment Monitoring, and Surveillance: A Pilot Study in Hematologic and Pediatric Malignancies

This is a prospective study that will look for the kinetics of circulating tumor DNA (ctDNA) in patients with hematologic and pediatric cancer before and after undergoing standard of care treatment regimens where radiation therapy is a treatment.

Age & Gender
  • 2 years ~ 99 years
  • Male, Female
Study Interest
  • Cancer (Pediatric Cancers, Lymphoma)
Open

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Have you been diagnosed with CD30 negative peripheral T-cell lymphoma? If so, you may be able to take part in a research study that will look at the safety of adding the new study drug duvelisib, or the new study drug CC-486, to the standard chemotherapy treatment for your disease. Please contact us with questions about eligibility, or if you wish to know more.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Lymphoma)
Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research